IMMUNEONCO-B (01541) Surges Over 16% Following IND Approval for Subcutaneous IMM0306S in Lupus Treatment

Stock News

Mar 06

IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on March 4th, when the company announced that the Investigational New Drug (IND) application for its self-developed Amurefup α subcutaneous injection (IMM0306S), intended for the treatment of Systemic Lupus Erythematosus (SLE), has received formal approval from China's National Medical Products Administration (NMPA). This milestone development signifies a major breakthrough for IMMUNEONCO in the research and development of innovative drugs for autoimmune diseases. The IND approval for IMM0306S to treat SLE represents the latest achievement in the company's intensive focus on the autoimmune disease area and is a key manifestation of its strategy for a comprehensive and flourishing autoimmune pipeline. In recent years, leveraging its "mAb-Trap" technology platform, IMM0306 has made critical progress across several major autoimmune indications, building a rich and deep product pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170058047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170058047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170058047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170058047","market":"sg","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Surges Over 16% Following IND Approval for Subcutaneous IMM0306S in Lupus Treatment","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on March 4th, when the company announced that the Investigational New Drug (IND) application for its self-developed Amurefup α subcutaneous injection (IMM0306S), intended for the treatment of Systemic Lupus Erythematosus (SLE), has received formal approval from China's National Medical Products Administration (NMPA). This milestone development signifies a major breakthrough for IMMUNEONCO in the research and development of innovative drugs for autoimmune diseases. The IND approval for IMM0306S to treat SLE represents the latest achievement in the company's intensive focus on the autoimmune disease area and is a key manifestation of its strategy for a comprehensive and flourishing autoimmune pipeline. In recent years, leveraging its \"mAb-Trap\" technology platform, IMM0306 has made critical progress across several major autoimmune indications, building a rich and deep product pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Surges Over 16% Following IND Approval for Subcutaneous IMM0306S in Lupus Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Surges Over 16% Following IND Approval for Subcutaneous IMM0306S in Lupus Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 11:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on March 4th, when the company announced that the Investigational New Drug (IND) application for its self-developed Amurefup α subcutaneous injection (IMM0306S), intended for the treatment of Systemic Lupus Erythematosus (SLE), has received formal approval from China's National Medical Products Administration (NMPA). This milestone development signifies a major breakthrough for IMMUNEONCO in the research and development of innovative drugs for autoimmune diseases. The IND approval for IMM0306S to treat SLE represents the latest achievement in the company's intensive focus on the autoimmune disease area and is a key manifestation of its strategy for a comprehensive and flourishing autoimmune pipeline. In recent years, leveraging its \"mAb-Trap\" technology platform, IMM0306 has made critical progress across several major autoimmune indications, building a rich and deep product pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1170058047","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170058047","pubTimestamp":1772769197,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","01541":"宜明昂科-B","BK4588":"碎股","BK1161":"生物科技","IND":"Xtrackers Nifty 500 India ETF","BK4585":"ETF&股票定投概念","VT":"世界全股市ETF-Vanguard"},"translate_title":"IMMUNEONCO-B(01541)在IND批准皮下IMM0306S治疗狼疮后股价飙升超过16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VT":1,"VXUS":1,"IND":1,"01541":1},"content_text":"IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on March 4th, when the company announced that the Investigational New Drug (IND) application for its self-developed Amurefup α subcutaneous injection (IMM0306S), intended for the treatment of Systemic Lupus Erythematosus (SLE), has received formal approval from China's National Medical Products Administration (NMPA). This milestone development signifies a major breakthrough for IMMUNEONCO in the research and development of innovative drugs for autoimmune diseases. The IND approval for IMM0306S to treat SLE represents the latest achievement in the company's intensive focus on the autoimmune disease area and is a key manifestation of its strategy for a comprehensive and flourishing autoimmune pipeline. In recent years, leveraging its \"mAb-Trap\" technology platform, IMM0306 has made critical progress across several major autoimmune indications, building a rich and deep product pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}